EBMT 2023 | Azacitidine and venetoclax maintenance post alloSCT in high-risk T-ALL
Nour Moukalled
• 25 Apr 2023
Nour Moukalled, MD, American University of Beirut, Beirut, Lebanon, comments on the potential of azacitidine and venetoclax as a maintenance strategy following allogeneic transplantation in high-risk T-cell acute lymphoblastic leukemia (T-ALL). In a recent case series, it was shown that this combination leads to effective disease control with a tolerable safety profile. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
